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Gregory L. Moneta, MD, Section EditorAbdominal Aortic Aneurysm Events in the Women’s Health Initiative:
Cohort Study
Lederle FA, Larson JC, Margolis KL, et al. BMJ 2008;337:1724.
Conclusion: There is a strong positive association with age and smok-
ing and abdominal aortic aneurysm (AAA) in women. There is a negative
association with diabetes.
Summary: Aortic aneurysms are more common in men but may be
more deadly in women. The Women’s Health Initiative (WHI) involved
clinical investigation of strategies of prevention of common diseases in
161,808 women. The authors used these data to assess for associations
between potential risk factors for AAA and subsequently clinically important
AAA events, rupture, and repair in postmenopausal women.
This was a cohort analysis of data from the WHI. Mean follow-up was
7.8 years. The WHI enrolled women who were postmenopausal and aged 50
to 79 years. The main outcome measure was the association of self-reported
or measured baseline variables with AAA repair or rupture. AAA events
occurred in 184 women. Events were strongly associated with age and
smoking. Ever smoked, current smoking, and amount smoked all contrib-
uted independent risks. Additional positive associations were seen for
height, cholesterol-lowering treatment, hypertension, and coronary and
peripheral arterial disease. There was a negative association with diabetes
(odd ratio, 0.29; 95% confidence interval, 0.13-0.68) and with postmeno-
pausal hormone therapy.
Comment: Although the incidence of AAA is significantly lower in
women than in men, most risk factors for AAA and negative associations
appear to be the same for men and women. The authors also found a
negative association between AAA in women and postmenopausal hormone
therapy, which suggests that estrogen may have a favorable effect in reducing
the development of AAA in women. However, other studies found increased
aneurysmal disease in patients treated with hormone therapy. It therefore
remains unclear why the prevalence of AAA differs so much by sex. One may
postulate a thus far unknown gender-associated biologic explanation. There
may also be unknown confounders of lifestyle in the WHI data. It does
appear, however, that the negative association between AAA and diabetes is
solid for both men and women.
Blunt Thoracic Aortic Injury: Open or Stent Graft Repair?
Yamane BH, Tefera G, Hoch JR, et al. Surgery 2008;144:575-82.
Conclusion:There are no significant differences between endovascular
and open repair of blunt aortic injury with respect to morbidity or mortality.
Summary: Endovascular stent grafting has nearly become the standard
of care for treatment of blunt thoracic aortic injury. This is despite the lack of
any randomized data to support this paradigm change in the treatment of
blunt aortic injury. The authors sought to determine whether the use of
endovascular stent grafting has actually improved outcome of treatment of
blunt thoracic aortic injury.
This was a retrospective review of the patients from single institution
that were treated for blunt thoracic aortic injury from October 1999 to May
2007. Patients were identified from the University of Wisconsin’s level I
trauma registry and included in this study if they had computed tomography
scan or angiographic evidence of a thoracic aortic injury distal to the left
subclavian artery after blunt trauma. Patients were separated into those who
underwent open repair (OR) and those who underwent endovascular repair
(ER). Patients were assessed for demographics, mechanism of injury, injury
severity score (ISS), associated injuries, known comorbid conditions, intra-
operative findings, postoperative complications, and hospital stay. Out-
comes in patients treated with OR and ER were compared.
During this 8-year period, 26 consecutive patients (20 men) were
treated for blunt aortic injury, of which 12 were treated with OR and 14 with
ER. The mean age was 36 years. There were no differences between the ER
and OR groups with respect to mechanism of injury, ISS score, or number of
associated injuries upon presentation. ER was technically successful in 100%,
with no procedurally related mortality. One patient in the OR group had a
presumed recurrent laryngeal nerve palsy postoperatively. There was no
treatment-related paraplegia in either group. One-year survival for OR and
ER patients was 93% and 92% respectively. At 1 year, 25% of patients in the
OR group and 18% in the ER group required reintervention. Intraoperative
blood product administration was greater in the OR group (P  .055).
However, total blood products transfused in the initial hospital stay did not
differ between the two groups. Duration of hospital stay was also similar, at
13 days for the OR group and 13.9 days for the ER group. Patients in the ER
group tended to have delayed repair vs those in the OR group, with anaverage time from injury to repair of 0.3 days for the OR group and 12.2
days for the ER group.
Comment: ER of thoracic aortic injury has its problems, but most
articles on this subject have concluded ER of blunt thoracic injury has
advantages over OR. This report will not significantly detract from the trend
for ER of blunt thoracic aortic injury. The number of patients treated here
was relatively small, averaging only about three patients per year. In addition,
the patients treated with OR had a mean cross-clamp time of 27 minutes
(these are quick surgeons), and half of the patients could be treated with
primary repair (favorable injuries). Overall survival of the OR group was
higher than is usually seen in reports of OR of thoracic aortic injury. This
suggests a relatively favorable group of patients treated with OR for blunt
thoracic injury at the University of Wisconsin. More data are clearly needed,
but despite this report, the trend for ER of blunt thoracic aortic injury will
continue.
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega JL, Close SL, Wiviott SD, et al. N Engl J Med 2009;360:354-62.
Conclusion: Persons with a reduced function of the CYP2C19 allele
have significantly lower levels of active metabolite of clopidogrel, with
diminished platelet inhibition and higher rates of major cardiovascular
events than noncarriers of the CYP2C19 allele.
Summary: Clopidogrel is a thienopyridine inhibitor of the platelet
P2Y12 adenosine diphosphate (ADP) receptor. It is a “prodrug” that re-
quires biotransformation to an active metabolite by a cytochrome P-450
enzyme. Esterases shunt most of clopidogrel to an inactive pathway, with the
remaining prodrug requiring two separate CYP-dependent oxidative steps.
Genes encoding CYP enzymes are polymorphic, with some alleles conferring
reduced enzymatic function. Therefore, it is possible CYP polymorphisms
can effect conversion of clopidogrel to active metabolite and hence affect the
degree of clopidogrel induced platelet inhibition.
In this study the authors tested the association between functional
variance in CYP genes, plasma concentration of active clopidogrel drug
metabolite, and platelet inhibition in response to clopidogrel. There were
162 healthy subjects analyzed as well as 1477 individuals with acute coronary
syndromes treated with clopidogrel in a trial to assess improvement in
therapeutic outcomes by optimizing platelet inhibition in patients with
myocardial infarction (TRITON-TIMI 38).
Approximately 30% of the healthy participants were carriers of at least
one CYP2C19 reduced-function allele. These individuals had a reduction of
32.4% in plasma exposure to the active metabolite of clopidogrel compared
with noncarriers (P .001). Carriers also had reduced reduction in maximal
platelet aggregation compared with noncarriers (P  .001). Among clopi-
dogrel-treated patients in TRITON-TIMI 38, carriers of reduced-function
alleles had a relative increase of 53% in the composite primary end point of
death due to cardiovascular causes, myocardial infarction, or stroke com-
pared with noncarriers (12.1% vs 8%; hazard ratio [HR] for carriers, 1.53;
95% confidence interval [CI] 1.07-2.19; P  .01). Carriers had an increase
by a factor of three in the risk of stent thrombosis (2.6% vs 0.8%; HR, 3.09;
95% CI, 1.19-8.00; P  .02).
Comment: This study, along with the similar study also appearing in
the same issue of theNew England Journal of Medicine (2009;360:363-75),
provides strong evidence linking genetic variations in CYP genes to reduced
exposure to active drug metabolite in patients treated with clopidogrel.
These polymorphisms are seen in approximately 30% of white patients, 40%
of African Americans, and 55% of people of East Asian origin. Of course
multiple other genetic and environmental factors can also contribute to
platelet aggregation. Nevertheless, the data are quite convincing that genetic
variation in the genes encoding CYP enzymes can result in meaningful and
profound clinical effects.
Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid
Atherosclerosis in Type 2 Diabetes
The SANDS (Stop Atherosclerosis in Native Diabetics Study) Trial. Fleg JL,
Mete M, Howard. J Am Coll Cardiol 2008;52:2198-205.
Conclusion: Reducing low-density lipoprotein cholesterol (LDL-C)
to aggressive target levels results in similar regression of carotid intimal
medial thickness (CIMT) in patients achieving equivalent LDL-C reduc-
tions using either a statin or statin plus ezetimibe. CIMT increases in patients
achieving only standard target levels for LDL-C.Summary: This is a secondary analysis from the SANDS (Stop Athero-
sclerosis in Native Diabetics Study) Trial. The goal was to examine the effects
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